RUBIUS THERAPEUTICS, INC. 6,896,552 Shares of Common Stock Underwriting AgreementLetter Agreement • March 18th, 2021 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 6,896,552 shares of common stock, $0.001 par value per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,034,482 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
